BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
0.4600
+0.0289 (6.70%)
Oct 26, 2026, 4:00 PM EDT - Market closed
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
18.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 13.79M |
| Kyntra Bio | 4.62M |
| Seres Therapeutics | 1.88M |
| Neuphoria Therapeutics | 1.17M |
| Cocrystal Pharma | 330.00K |
BYSI News
- 27 days ago - BeyondSpring Transcript: FDA announcement - Transcripts
- 27 days ago - BeyondSpring Press release: FDA announcement - Filings
- 27 days ago - BeyondSpring announces U.S. FDA granted Fast Track designation to Plinabulin - TheFly
- 27 days ago - BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis - GlobeNewsWire
- 7 weeks ago - BeyondSpring Proxy statement: Proxy filing - Filings
- 7 weeks ago - BeyondSpring Proxy statement: Proxy filing - Filings
- 1 month ago - BeyondSpring Slides: Investor presentation - Filings
- 2 months ago - BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire